Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.74 SEK | +4.72% | +8.86% | +13.51% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 239M 22.12M | Sales 2025 * | 343M 31.68M | Capitalization | 1.64B 151M |
---|---|---|---|---|---|
Net income 2024 * | -735M -67.96M | Net income 2025 * | -712M -65.84M | EV / Sales 2024 * | 8.82 x |
Net Debt 2024 * | 474M 43.83M | Net Debt 2025 * | 733M 67.81M | EV / Sales 2025 * | 6.92 x |
P/E ratio 2024 * |
-2.58
x | P/E ratio 2025 * |
-3.06
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.64% |
Latest transcript on Hansa Biopharma AB
1 day | +4.72% | ||
1 week | +8.86% | ||
Current month | +2.76% | ||
1 month | -3.57% | ||
3 months | -5.04% | ||
6 months | +28.30% | ||
Current year | +13.51% |
Managers | Title | Age | Since |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 18-03-19 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | Nov. 30 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 20-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 18-05-28 | |
Peter Nicklin
CHM | Chairman | 61 | 22-06-29 |
Mats Blom
BRD | Director/Board Member | 59 | 19-05-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 29.74 | +4.72% | 208,900 |
24-05-02 | 28.4 | -1.87% | 125,328 |
24-04-30 | 28.94 | -0.21% | 32,739 |
24-04-29 | 29 | +6.15% | 148,164 |
24-04-26 | 27.32 | +0.44% | 257,784 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.51% | 152M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+28.07% | 12.14B | |
+0.17% | 12.15B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- HNSA Stock